ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

• The average 12-month price target on the stock is $18, representing a potential upside of as much as 495% from the stock’s current $3.02 trading levels.
• The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026.
• Truist believes that pemvidutide "could be successful in treating MASH as well as liver-related diseases AUD."

Shares of Altimmune (ALT) traded 5% lower on Friday despite Wall Street viewing a potential upside of as much as 495% on the stock.

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.

The average 12-month price target on the stock is $18, compared to the stock’s current $3.02 trading levels.

Wall Street Take

Earlier this month, Truist initiated coverage of Altimmune with a ‘Buy’ rating and $12 price target. The firm believes that the company's lead candidate pemvidutide "could be successful in treating MASH."

Truist is modelling peak 20,000 patients on pemvidutide, which would result in worldwide "peak adjusted/unadjusted revenue of ~$600million/$1.0billion," it said.

Altimmune Pipeline

Altimmune is a clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). The company’s pemvidutide is in development for the treatment of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in addition to MASH.

The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026. The trial is expected to evaluate multiple pemvidutide doses over a 52-week treatment period.

The company is looking forward to announcing topline data from a mid–stage trial of pemvidutide in Alcohol Use Disorder in the third quarter of 2026, and is also enrolling patients into a mid-stage trial of the drug in Alcohol-associated Liver Disease.

Retail Sentiment

On Stocktwits, retail sentiment around ALT stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.

A Stocktwits user expressed disappointment about the stock’s downward trajectory.

ALT stock has dropped 45% over the past 12 months.

Read More: RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

For updates and corrections, email newsroom[at]stocktwits[dot]com.